Global and Japan Pulmonary Hypertension Drug Market Insights, Forecast to 2026

Global and Japan Pulmonary Hypertension Drug Market Insights, Forecast to 2026

Table of Contents
1 Study Coverage
1.1 Pulmonary Hypertension Drug Product Introduction
1.2 Market Segments
1.3 Key Pulmonary Hypertension Drug Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Pulmonary Hypertension Drug Market Size Growth Rate by Type
1.4.2 IK-3001
1.4.3 Sildenafil Citrate IMD
1.4.4 IK-7002
1.4.5 Riociguat
1.4.6 SAR-407899
1.4.7 Others
1.5 Market by Application
1.5.1 Global Pulmonary Hypertension Drug Market Size Growth Rate by Application
1.5.2 Clinic
1.5.3 Hospital
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Pulmonary Hypertension Drug Market Size, Estimates and Forecasts
2.1.1 Global Pulmonary Hypertension Drug Revenue 2015-2026
2.1.2 Global Pulmonary Hypertension Drug Sales 2015-2026
2.2 Global Pulmonary Hypertension Drug, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.3 Pulmonary Hypertension Drug Historical Market Size by Region (2015-2020)
2.3.1 Global Pulmonary Hypertension Drug Retrospective Market Scenario in Sales by Region: 2015-2020
2.3.2 Global Pulmonary Hypertension Drug Retrospective Market Scenario in Revenue by Region: 2015-2020
2.4 Pulmonary Hypertension Drug Market Estimates and Projections by Region (2021-2026)
2.4.1 Global Pulmonary Hypertension Drug Sales Forecast by Region (2021-2026)
2.4.2 Global Pulmonary Hypertension Drug Revenue Forecast by Region (2021-2026)
3 Global Pulmonary Hypertension Drug Competitor Landscape by Players
3.1 Global Top Pulmonary Hypertension Drug Sales by Manufacturers
3.1.1 Global Pulmonary Hypertension Drug Sales by Manufacturers (2015-2020)
3.1.2 Global Pulmonary Hypertension Drug Sales Market Share by Manufacturers (2015-2020)
3.2 Global Pulmonary Hypertension Drug Manufacturers by Revenue
3.2.1 Global Pulmonary Hypertension Drug Revenue by Manufacturers (2015-2020)
3.2.2 Global Pulmonary Hypertension Drug Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Pulmonary Hypertension Drug Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Pulmonary Hypertension Drug Revenue in 2019
3.2.5 Global Pulmonary Hypertension Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Global Pulmonary Hypertension Drug Price by Manufacturers
3.4 Global Pulmonary Hypertension Drug Manufacturing Base Distribution, Product Types
3.4.1 Pulmonary Hypertension Drug Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Pulmonary Hypertension Drug Product Type
3.4.3 Date of International Manufacturers Enter into Pulmonary Hypertension Drug Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Pulmonary Hypertension Drug Market Size by Type (2015-2020)
4.1.1 Global Pulmonary Hypertension Drug Sales by Type (2015-2020)
4.1.2 Global Pulmonary Hypertension Drug Revenue by Type (2015-2020)
4.1.3 Pulmonary Hypertension Drug Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Pulmonary Hypertension Drug Market Size Forecast by Type (2021-2026)
4.2.1 Global Pulmonary Hypertension Drug Sales Forecast by Type (2021-2026)
4.2.2 Global Pulmonary Hypertension Drug Revenue Forecast by Type (2021-2026)
4.2.3 Pulmonary Hypertension Drug Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Pulmonary Hypertension Drug Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Pulmonary Hypertension Drug Market Size by Application (2015-2020)
5.1.1 Global Pulmonary Hypertension Drug Sales by Application (2015-2020)
5.1.2 Global Pulmonary Hypertension Drug Revenue by Application (2015-2020)
5.1.3 Pulmonary Hypertension Drug Price by Application (2015-2020)
5.2 Pulmonary Hypertension Drug Market Size Forecast by Application (2021-2026)
5.2.1 Global Pulmonary Hypertension Drug Sales Forecast by Application (2021-2026)
5.2.2 Global Pulmonary Hypertension Drug Revenue Forecast by Application (2021-2026)
5.2.3 Global Pulmonary Hypertension Drug Price Forecast by Application (2021-2026)
6 Japan by Players, Type and Application
6.1 Japan Pulmonary Hypertension Drug Market Size YoY Growth 2015-2026
6.1.1 Japan Pulmonary Hypertension Drug Sales YoY Growth 2015-2026
6.1.2 Japan Pulmonary Hypertension Drug Revenue YoY Growth 2015-2026
6.1.3 Japan Pulmonary Hypertension Drug Market Share in Global Market 2015-2026
6.2 Japan Pulmonary Hypertension Drug Market Size by Players (International and Local Players)
6.2.1 Japan Top Pulmonary Hypertension Drug Players by Sales (2015-2020)
6.2.2 Japan Top Pulmonary Hypertension Drug Players by Revenue (2015-2020)
6.3 Japan Pulmonary Hypertension Drug Historic Market Review by Type (2015-2020)
6.3.1 Japan Pulmonary Hypertension Drug Sales Market Share by Type (2015-2020)
6.3.2 Japan Pulmonary Hypertension Drug Revenue Market Share by Type (2015-2020)
6.3.3 Japan Pulmonary Hypertension Drug Price by Type (2015-2020)
6.4 Japan Pulmonary Hypertension Drug Market Estimates and Forecasts by Type (2021-2026)
6.4.1 Japan Pulmonary Hypertension Drug Sales Forecast by Type (2021-2026)
6.4.2 Japan Pulmonary Hypertension Drug Revenue Forecast by Type (2021-2026)
6.4.3 Japan Pulmonary Hypertension Drug Price Forecast by Type (2021-2026)
6.5 Japan Pulmonary Hypertension Drug Historic Market Review by Application (2015-2020)
6.5.1 Japan Pulmonary Hypertension Drug Sales Market Share by Application (2015-2020)
6.5.2 Japan Pulmonary Hypertension Drug Revenue Market Share by Application (2015-2020)
6.5.3 Japan Pulmonary Hypertension Drug Price by Application (2015-2020)
6.6 Japan Pulmonary Hypertension Drug Market Estimates and Forecasts by Application (2021-2026)
6.6.1 Japan Pulmonary Hypertension Drug Sales Forecast by Application (2021-2026)
6.6.2 Japan Pulmonary Hypertension Drug Revenue Forecast by Application (2021-2026)
6.6.3 Japan Pulmonary Hypertension Drug Price Forecast by Application (2021-2026)
7 North America
7.1 North America Pulmonary Hypertension Drug Market Size YoY Growth 2015-2026
7.2 North America Pulmonary Hypertension Drug Market Facts & Figures by Country
7.2.1 North America Pulmonary Hypertension Drug Sales by Country (2015-2020)
7.2.2 North America Pulmonary Hypertension Drug Revenue by Country (2015-2020)
7.2.3 U.S.
7.2.4 Canada
8 Europe
8.1 Europe Pulmonary Hypertension Drug Market Size YoY Growth 2015-2026
8.2 Europe Pulmonary Hypertension Drug Market Facts & Figures by Country
8.2.1 Europe Pulmonary Hypertension Drug Sales by Country
8.2.2 Europe Pulmonary Hypertension Drug Revenue by Country
8.2.3 Germany
8.2.4 France
8.2.5 U.K.
8.2.6 Italy
8.2.7 Russia
9 Asia Pacific
9.1 Asia Pacific Pulmonary Hypertension Drug Market Size YoY Growth 2015-2026
9.2 Asia Pacific Pulmonary Hypertension Drug Market Facts & Figures by Country
9.2.1 Asia Pacific Pulmonary Hypertension Drug Sales by Region (2015-2020)
9.2.2 Asia Pacific Pulmonary Hypertension Drug Revenue by Region
9.2.3 China
9.2.4 Japan
9.2.5 South Korea
9.2.6 India
9.2.7 Australia
9.2.8 Taiwan
9.2.9 Indonesia
9.2.10 Thailand
9.2.11 Malaysia
9.2.12 Philippines
9.2.13 Vietnam
10 Latin America
10.1 Latin America Pulmonary Hypertension Drug Market Size YoY Growth 2015-2026
10.2 Latin America Pulmonary Hypertension Drug Market Facts & Figures by Country
10.2.1 Latin America Pulmonary Hypertension Drug Sales by Country
10.2.2 Latin America Pulmonary Hypertension Drug Revenue by Country
10.2.3 Mexico
10.2.4 Brazil
10.2.5 Argentina
11 Middle East and Africa
11.1 Middle East and Africa Pulmonary Hypertension Drug Market Size YoY Growth 2015-2026
11.2 Middle East and Africa Pulmonary Hypertension Drug Market Facts & Figures by Country
11.2.1 Middle East and Africa Pulmonary Hypertension Drug Sales by Country
11.2.2 Middle East and Africa Pulmonary Hypertension Drug Revenue by Country
11.2.3 Turkey
11.2.4 Saudi Arabia
11.2.5 U.A.E
12 Company Profiles
12.1 Sanofi
12.1.1 Sanofi Corporation Information
12.1.2 Sanofi Description and Business Overview
12.1.3 Sanofi Sales, Revenue and Gross Margin (2015-2020)
12.1.4 Sanofi Pulmonary Hypertension Drug Products Offered
12.1.5 Sanofi Recent Development
12.2 Vectura Group plc
12.2.1 Vectura Group plc Corporation Information
12.2.2 Vectura Group plc Description and Business Overview
12.2.3 Vectura Group plc Sales, Revenue and Gross Margin (2015-2020)
12.2.4 Vectura Group plc Pulmonary Hypertension Drug Products Offered
12.2.5 Vectura Group plc Recent Development
12.3 Bayer AG
12.3.1 Bayer AG Corporation Information
12.3.2 Bayer AG Description and Business Overview
12.3.3 Bayer AG Sales, Revenue and Gross Margin (2015-2020)
12.3.4 Bayer AG Pulmonary Hypertension Drug Products Offered
12.3.5 Bayer AG Recent Development
12.4 Ikaria Inc.
12.4.1 Ikaria Inc. Corporation Information
12.4.2 Ikaria Inc. Description and Business Overview
12.4.3 Ikaria Inc. Sales, Revenue and Gross Margin (2015-2020)
12.4.4 Ikaria Inc. Pulmonary Hypertension Drug Products Offered
12.4.5 Ikaria Inc. Recent Development
12.5 Proreo Pharma AG
12.5.1 Proreo Pharma AG Corporation Information
12.5.2 Proreo Pharma AG Description and Business Overview
12.5.3 Proreo Pharma AG Sales, Revenue and Gross Margin (2015-2020)
12.5.4 Proreo Pharma AG Pulmonary Hypertension Drug Products Offered
12.5.5 Proreo Pharma AG Recent Development
12.6 Vicore Pharma AB
12.6.1 Vicore Pharma AB Corporation Information
12.6.2 Vicore Pharma AB Description and Business Overview
12.6.3 Vicore Pharma AB Sales, Revenue and Gross Margin (2015-2020)
12.6.4 Vicore Pharma AB Pulmonary Hypertension Drug Products Offered
12.6.5 Vicore Pharma AB Recent Development
12.7 Biolab Sanus Farmaceutica Ltda.
12.7.1 Biolab Sanus Farmaceutica Ltda. Corporation Information
12.7.2 Biolab Sanus Farmaceutica Ltda. Description and Business Overview
12.7.3 Biolab Sanus Farmaceutica Ltda. Sales, Revenue and Gross Margin (2015-2020)
12.7.4 Biolab Sanus Farmaceutica Ltda. Pulmonary Hypertension Drug Products Offered
12.7.5 Biolab Sanus Farmaceutica Ltda. Recent Development
12.8 Hanmi Pharmaceuticals, Co. Ltd.
12.8.1 Hanmi Pharmaceuticals, Co. Ltd. Corporation Information
12.8.2 Hanmi Pharmaceuticals, Co. Ltd. Description and Business Overview
12.8.3 Hanmi Pharmaceuticals, Co. Ltd. Sales, Revenue and Gross Margin (2015-2020)
12.8.4 Hanmi Pharmaceuticals, Co. Ltd. Pulmonary Hypertension Drug Products Offered
12.8.5 Hanmi Pharmaceuticals, Co. Ltd. Recent Development
12.11 Sanofi
12.11.1 Sanofi Corporation Information
12.11.2 Sanofi Description and Business Overview
12.11.3 Sanofi Sales, Revenue and Gross Margin (2015-2020)
12.11.4 Sanofi Pulmonary Hypertension Drug Products Offered
12.11.5 Sanofi Recent Development
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter's Five Forces Analysis
13.5 Primary Interviews with Key Pulmonary Hypertension Drug Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Pulmonary Hypertension Drug Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
List of Tables
Table 1. Pulmonary Hypertension Drug Market Segments
Table 2. Ranking of Global Top Pulmonary Hypertension Drug Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Pulmonary Hypertension Drug Market Size Growth Rate by Type 2020-2026 (K Pcs) & (US$ Million)
Table 4. Major Manufacturers of IK-3001
Table 5. Major Manufacturers of Sildenafil Citrate IMD
Table 6. Major Manufacturers of IK-7002
Table 7. Major Manufacturers of Riociguat
Table 8. Major Manufacturers of SAR-407899
Table 9. Major Manufacturers of Others
Table 10. Global Pulmonary Hypertension Drug Market Size Growth Rate by Application 2020-2026 (K Pcs)
Table 11. Global Pulmonary Hypertension Drug Market Size by Region (K Pcs) & (US$ Million): 2020 VS 2026
Table 12. Global Pulmonary Hypertension Drug Sales by Regions 2015-2020 (K Pcs)
Table 13. Global Pulmonary Hypertension Drug Sales Market Share by Regions (2015-2020)
Table 14. Global Pulmonary Hypertension Drug Revenue by Regions 2015-2020 (US$ Million)
Table 15. Global Pulmonary Hypertension Drug Sales Forecast by Region (2021-2026) (K Pcs)
Table 16. Global Pulmonary Hypertension Drug Sales by Manufacturers (2015-2020) (K Pcs)
Table 17. Global Pulmonary Hypertension Drug Sales Share by Manufacturers (2015-2020)
Table 18. Global Pulmonary Hypertension Drug Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 19. Global Pulmonary Hypertension Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Pulmonary Hypertension Drug as of 2019)
Table 20. Pulmonary Hypertension Drug Revenue by Manufacturers (2015-2020) (US$ Million)
Table 21. Pulmonary Hypertension Drug Revenue Share by Manufacturers (2015-2020)
Table 22. Key Manufacturers Pulmonary Hypertension Drug Price (2015-2020) (USD/Pcs)
Table 23. Pulmonary Hypertension Drug Manufacturers Manufacturing Base Distribution and Headquarters
Table 24. Manufacturers Pulmonary Hypertension Drug Product Type
Table 25. Date of International Manufacturers Enter into Pulmonary Hypertension Drug Market
Table 26. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 27. Global Pulmonary Hypertension Drug Sales by Type (2015-2020) (K Pcs)
Table 28. Global Pulmonary Hypertension Drug Sales Share by Type (2015-2020)
Table 29. Global Pulmonary Hypertension Drug Revenue by Type (2015-2020) (US$ Million)
Table 30. Global Pulmonary Hypertension Drug Revenue Share by Type (2015-2020)
Table 31. Pulmonary Hypertension Drug Average Selling Price (ASP) by Type 2015-2020 (USD/Pcs)
Table 32. Global Pulmonary Hypertension Drug Sales Share by Type (2021-2026)
Table 33. Global Pulmonary Hypertension Drug Sales by Application (2015-2020) (K Pcs)
Table 34. Global Pulmonary Hypertension Drug Sales Share by Application (2015-2020)
Table 35. Global Pulmonary Hypertension Drug Sales Share by Application (2021-2026)
Table 36. Global Pulmonary Hypertension Drug Sales Market Share Forecast by Application (2021-2026)
Table 37. Global Pulmonary Hypertension Drug Revenue by Application (2015-2020) (US$ Million)
Table 38. Global Pulmonary Hypertension Drug Revenue Market Share Forecast by Application (2021-2026)
Table 39. Japan Pulmonary Hypertension Drug Sales (K Pcs) of Key Companies (2015-2020)
Table 40. Japan Pulmonary Hypertension Drug Sales Share by Company (2015-2020)
Table 41. Japan Pulmonary Hypertension Drug Revenue (US$ Million) by Company (2015-2020)
Table 42. Japan Pulmonary Hypertension Drug Sales (K Pcs) by Type (2015-2020)
Table 43. Japan Pulmonary Hypertension Drug Sales Share by Type (2015-2020)
Table 44. Japan Pulmonary Hypertension Drug Revenue (US$ Million) Market Share by Type (2015-2020)
Table 45. Japan Pulmonary Hypertension Drug Price (K Pcs) by Type (2015-2020)
Table 46. Japan Pulmonary Hypertension Drug Sales (K Pcs) by Type (2021-2026)
Table 47. Japan Pulmonary Hypertension Drug Sales Share by Type (2021-2026)
Table 48. Japan Pulmonary Hypertension Drug Revenue (US$ Million) Market Share by Type (2021-2026)
Table 49. Japan Pulmonary Hypertension Drug Revenue Share by Type (2021-2026)
Table 50. Japan Pulmonary Hypertension Drug Price (K Pcs) by Type (2021-2026)
Table 51. Japan Pulmonary Hypertension Drug Sales (K Pcs) by Application (2015-2020)
Table 52. Japan Pulmonary Hypertension Drug Sales Share by Application (2015-2020)
Table 53. Japan Pulmonary Hypertension Drug Revenue (US$ Million) Market Share by Application (2015-2020)
Table 54. Japan Pulmonary Hypertension Drug Sales (K Pcs) by Application (2021-2026)
Table 55. Japan Pulmonary Hypertension Drug Sales Share by Application (2021-2026)
Table 56. Japan Pulmonary Hypertension Drug Revenue (US$ Million) Market Share by Application (2021-2026)
Table 57. Japan Pulmonary Hypertension Drug Revenue Share by Application (2021-2026)
Table 58. North America Pulmonary Hypertension Drug Sales by Country (2015-2020) (K Pcs)
Table 59. North America Pulmonary Hypertension Drug Sales Market Share by Country (2015-2020)
Table 60. North America Pulmonary Hypertension Drug Revenue by Country (2015-2020) (US$ Million)
Table 61. North America Pulmonary Hypertension Drug Revenue Market Share by Country (2015-2020)
Table 62. Europe Pulmonary Hypertension Drug Sales by Country (2015-2020) (K Pcs)
Table 63. Europe Pulmonary Hypertension Drug Sales Market Share by Country (2015-2020)
Table 64. Europe Pulmonary Hypertension Drug Revenue by Country (2015-2020) (US$ Million)
Table 65. Europe Pulmonary Hypertension Drug Revenue Market Share by Country (2015-2020)
Table 66. Asia Pacific Pulmonary Hypertension Drug Sales by Region (2015-2020) (K Pcs)
Table 67. Asia Pacific Pulmonary Hypertension Drug Sales Market Share by Region (2015-2020)
Table 68. Asia Pacific Pulmonary Hypertension Drug Revenue by Region (2015-2020) (US$ Million)
Table 69. Asia Pacific Pulmonary Hypertension Drug Revenue Market Share by Region (2015-2020)
Table 70. Latin America Pulmonary Hypertension Drug Sales by Country (2015-2020) (K Pcs)
Table 71. Latin America Pulmonary Hypertension Drug Sales Market Share by Country (2015-2020)
Table 72. Latin Americaa Pulmonary Hypertension Drug Revenue by Country (2015-2020) (US$ Million)
Table 73. Latin America Pulmonary Hypertension Drug Revenue Market Share by Country (2015-2020)
Table 74. Middle East and Africa Pulmonary Hypertension Drug Sales by Country (2015-2020) (K Pcs)
Table 75. Middle East and Africa Pulmonary Hypertension Drug Sales Market Share by Country (2015-2020)
Table 76. Middle East and Africa Pulmonary Hypertension Drug Revenue by Country (2015-2020) (US$ Million)
Table 77. Middle East and Africa Pulmonary Hypertension Drug Revenue Market Share by Country (2015-2020)
Table 78. Sanofi Corporation Information
Table 79. Sanofi Description and Business Overview
Table 80. Sanofi Pulmonary Hypertension Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 81. Sanofi Pulmonary Hypertension Drug Product
Table 82. Sanofi Recent Development
Table 83. Vectura Group plc Corporation Information
Table 84. Vectura Group plc Description and Business Overview
Table 85. Vectura Group plc Pulmonary Hypertension Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 86. Vectura Group plc Product
Table 87. Vectura Group plc Recent Development
Table 88. Bayer AG Corporation Information
Table 89. Bayer AG Description and Business Overview
Table 90. Bayer AG Pulmonary Hypertension Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 91. Bayer AG Product
Table 92. Bayer AG Recent Development
Table 93. Ikaria Inc. Corporation Information
Table 94. Ikaria Inc. Description and Business Overview
Table 95. Ikaria Inc. Pulmonary Hypertension Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 96. Ikaria Inc. Product
Table 97. Ikaria Inc. Recent Development
Table 98. Proreo Pharma AG Corporation Information
Table 99. Proreo Pharma AG Description and Business Overview
Table 100. Proreo Pharma AG Pulmonary Hypertension Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 101. Proreo Pharma AG Product
Table 102. Proreo Pharma AG Recent Development
Table 103. Vicore Pharma AB Corporation Information
Table 104. Vicore Pharma AB Description and Business Overview
Table 105. Vicore Pharma AB Pulmonary Hypertension Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 106. Vicore Pharma AB Product
Table 107. Vicore Pharma AB Recent Development
Table 108. Biolab Sanus Farmaceutica Ltda. Corporation Information
Table 109. Biolab Sanus Farmaceutica Ltda. Description and Business Overview
Table 110. Biolab Sanus Farmaceutica Ltda. Pulmonary Hypertension Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 111. Biolab Sanus Farmaceutica Ltda. Product
Table 112. Biolab Sanus Farmaceutica Ltda. Recent Development
Table 113. Hanmi Pharmaceuticals, Co. Ltd. Corporation Information
Table 114. Hanmi Pharmaceuticals, Co. Ltd. Description and Business Overview
Table 115. Hanmi Pharmaceuticals, Co. Ltd. Pulmonary Hypertension Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 116. Hanmi Pharmaceuticals, Co. Ltd. Product
Table 117. Hanmi Pharmaceuticals, Co. Ltd. Recent Development
Table 118. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 119. Key Challenges
Table 120. Market Risks
Table 121. Main Points Interviewed from Key Pulmonary Hypertension Drug Players
Table 122. Pulmonary Hypertension Drug Customers List
Table 123. Pulmonary Hypertension Drug Distributors List
Table 124. Research Programs/Design for This Report
Table 125. Key Data Information from Secondary Sources
Table 126. Key Data Information from Primary Sources
List of Figures
Figure 1. Pulmonary Hypertension Drug Product Picture
Figure 2. Global Pulmonary Hypertension Drug Sales Market Share by Type in 2020 & 2026
Figure 3. IK-3001 Product Picture
Figure 4. Sildenafil Citrate IMD Product Picture
Figure 5. IK-7002 Product Picture
Figure 6. Riociguat Product Picture
Figure 7. SAR-407899 Product Picture
Figure 8. Others Product Picture
Figure 9. Global Pulmonary Hypertension Drug Sales Market Share by Application in 2020 & 2026
Figure 10. Clinic
Figure 11. Hospital
Figure 12. Others
Figure 13. Pulmonary Hypertension Drug Report Years Considered
Figure 14. Global Pulmonary Hypertension Drug Market Size 2015-2026 (US$ Million)
Figure 15. Global Pulmonary Hypertension Drug Sales 2015-2026 (K Pcs)
Figure 16. Global Pulmonary Hypertension Drug Market Size Market Share by Region: 2020 Versus 2026
Figure 17. Global Pulmonary Hypertension Drug Sales Market Share by Region (2015-2020)
Figure 18. Global Pulmonary Hypertension Drug Sales Market Share by Region in 2019
Figure 19. Global Pulmonary Hypertension Drug Revenue Market Share by Region (2015-2020)
Figure 20. Global Pulmonary Hypertension Drug Revenue Market Share by Region in 2019
Figure 21. Global Pulmonary Hypertension Drug Sales Share by Manufacturer in 2019
Figure 22. The Top 10 and 5 Players Market Share by Pulmonary Hypertension Drug Revenue in 2019
Figure 23. Pulmonary Hypertension Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 24. Global Pulmonary Hypertension Drug Sales Market Share by Type (2015-2020)
Figure 25. Global Pulmonary Hypertension Drug Sales Market Share by Type in 2019
Figure 26. Global Pulmonary Hypertension Drug Revenue Market Share by Type (2015-2020)
Figure 27. Global Pulmonary Hypertension Drug Revenue Market Share by Type in 2019
Figure 28. Global Pulmonary Hypertension Drug Market Share by Price Range (2015-2020)
Figure 29. Global Pulmonary Hypertension Drug Sales Market Share by Application (2015-2020)
Figure 30. Global Pulmonary Hypertension Drug Sales Market Share by Application in 2019
Figure 31. Global Pulmonary Hypertension Drug Revenue Market Share by Application (2015-2020)
Figure 32. Global Pulmonary Hypertension Drug Revenue Market Share by Application in 2019
Figure 33. Japan Pulmonary Hypertension Drug Sales Growth Rate 2015-2026 (K Pcs)
Figure 34. Japan Pulmonary Hypertension Drug Revenue Growth Rate 2015-2026 (US$ Million)
Figure 35. Japan Pulmonary Hypertension Drug Market Share in Global Market 2015-2026
Figure 36. Japan 5 and 10 Largest Pulmonary Hypertension Drug Players Market Share by Revenue in Pulmonary Hypertension Drug in 2019
Figure 37. Japan Pulmonary Hypertension Drug Revenue Share by Type (2015-2020)
Figure 38. Japan Pulmonary Hypertension Drug Revenue Growth Rate by Type in 2015 & 2019
Figure 39. Japan Pulmonary Hypertension Drug Revenue Share by Application (2015-2020)
Figure 40. Japan Pulmonary Hypertension Drug Revenue Growth Rate by Application in 2015 & 2019
Figure 41. North America Pulmonary Hypertension Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 42. North America Pulmonary Hypertension Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 43. North America Pulmonary Hypertension Drug Sales Market Share by Country in 2019
Figure 44. North America Pulmonary Hypertension Drug Revenue Market Share by Country in 2019
Figure 45. U.S. Pulmonary Hypertension Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 46. U.S. Pulmonary Hypertension Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 47. Canada Pulmonary Hypertension Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 48. Canada Pulmonary Hypertension Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 49. Europe Pulmonary Hypertension Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 50. Europe Pulmonary Hypertension Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 51. Europe Pulmonary Hypertension Drug Sales Market Share by Country in 2019
Figure 52. Europe Pulmonary Hypertension Drug Revenue Market Share by Country in 2019
Figure 53. Germany Pulmonary Hypertension Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 54. Germany Pulmonary Hypertension Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 55. France Pulmonary Hypertension Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 56. France Pulmonary Hypertension Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 57. U.K. Pulmonary Hypertension Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 58. U.K. Pulmonary Hypertension Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 59. Italy Pulmonary Hypertension Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 60. Italy Pulmonary Hypertension Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 61. Russia Pulmonary Hypertension Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 62. Russia Pulmonary Hypertension Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 63. Asia Pacific Pulmonary Hypertension Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 64. Asia Pacific Pulmonary Hypertension Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 65. Asia Pacific Pulmonary Hypertension Drug Sales Market Share by Region in 2019
Figure 66. Asia Pacific Pulmonary Hypertension Drug Revenue Market Share by Region in 2019
Figure 67. China Pulmonary Hypertension Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 68. China Pulmonary Hypertension Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 69. Japan Pulmonary Hypertension Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 70. Japan Pulmonary Hypertension Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 71. South Korea Pulmonary Hypertension Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 72. South Korea Pulmonary Hypertension Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 73. India Pulmonary Hypertension Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 74. India Pulmonary Hypertension Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 75. Australia Pulmonary Hypertension Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 76. Australia Pulmonary Hypertension Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 77. Taiwan Pulmonary Hypertension Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 78. Taiwan Pulmonary Hypertension Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 79. Indonesia Pulmonary Hypertension Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 80. Indonesia Pulmonary Hypertension Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 81. Thailand Pulmonary Hypertension Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 82. Thailand Pulmonary Hypertension Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 83. Malaysia Pulmonary Hypertension Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 84. Malaysia Pulmonary Hypertension Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 85. Philippines Pulmonary Hypertension Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 86. Philippines Pulmonary Hypertension Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 87. Vietnam Pulmonary Hypertension Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 88. Vietnam Pulmonary Hypertension Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 89. Latin America Pulmonary Hypertension Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 90. Latin America Pulmonary Hypertension Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 91. Latin America Pulmonary Hypertension Drug Sales Market Share by Country in 2019
Figure 92. Latin America Pulmonary Hypertension Drug Revenue Market Share by Country in 2019
Figure 93. Mexico Pulmonary Hypertension Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 94. Mexico Pulmonary Hypertension Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 95. Brazil Pulmonary Hypertension Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 96. Brazil Pulmonary Hypertension Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 97. Argentina Pulmonary Hypertension Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 98. Argentina Pulmonary Hypertension Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 99. Middle East and Africa Pulmonary Hypertension Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 100. Middle East and Africa Pulmonary Hypertension Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 101. Middle East and Africa Pulmonary Hypertension Drug Sales Market Share by Country in 2019
Figure 102. Middle East and Africa Pulmonary Hypertension Drug Revenue Market Share by Country in 2019
Figure 103. Turkey Pulmonary Hypertension Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 104. Turkey Pulmonary Hypertension Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 105. Saudi Arabia Pulmonary Hypertension Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 106. Saudi Arabia Pulmonary Hypertension Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 107. U.A.E Pulmonary Hypertension Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 108. U.A.E Pulmonary Hypertension Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 109. Porter's Five Forces Analysis
Figure 110. Pulmonary Hypertension Drug Value Chain
Figure 111. Channels of Distribution
Figure 112. Distributors Profiles
Figure 113. Bottom-up and Top-down Approaches for This Report
Figure 114. Data Triangulation
Figure 115. Key Executives Interviewed

• Clinical Results in Diabetics To Be Boosted By Smart Artificial Beta Cells

For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…

• High-speed Data Transmission And High Volume Needs Propel Fiber Optic Connectors Market

Fiber optic connectors are a substantial fragment of the global telecommunication industry. Optical fibers are joined using fiber optic connectors, which allow the light conduction between two consecutive optical fibers. An additional im…

• Extensive Use of Digital Technologies for Diagnostic Applications To Boost Global Optical Imaging Market

The global optical imaging system market is predicted to reach US$ 3 billion by 2024. It is expected to grow at a stable rate and will post a CAGR of more than 8% in the coming years. The growing market infiltration of digital …

• Foremost Trends In Global Pet Care Market

The global pet care market is foretold to improve in the forthcoming years as matched to the preceding years and will showcase better sales in various market segments. It is estimated that the global pet care market will grow at a CAGR o…

• China To Review Its Food Security Laws

China has arisen as the globe’s firmest developing economy. In addition, China brags about the biggest population pool in the world. In recent times, the one child policy in the republic was terminated. This is anticipated to upsur…

Global Antioxidant Vitamins Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 100

The global Antioxidant Vitamins market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Antioxidant Vitamins is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Antioxidant Vitamins is estimated to increase from $ million in 2023 to reach $ millio......

Global Clavulanate Potassium Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 86

The global Clavulanate Potassium market was valued at US$ 446.6 million in 2023 and is anticipated to reach US$ 637.2 million by 2030, witnessing a CAGR of 5.2% during The forecast period 2024-2030. North American market for Clavulanate Potassium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Clavulanate Potassium is estimated to increase from $ million in 2023......

Global Amoxicillin Sodium Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 84

The global Amoxicillin Sodium market was valued at US$ 460.9 million in 2023 and is anticipated to reach US$ 735.1 million by 2030, witnessing a CAGR of 7.0% during The forecast period 2024-2030. North American market for Amoxicillin Sodium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Amoxicillin Sodium is estimated to increase from $ million in 2023 to reach......

Global Melatonin Supplements Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 106

The global Melatonin Supplements market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Melatonin Supplements is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Melatonin Supplements is estimated to increase from $ million in 2023 to reach $ mil......

Global Sleeping Pills (Prescription Drugs) Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 93

The global Sleeping Pills (Prescription Drugs) market was valued at US$ 1022.3 million in 2023 and is anticipated to reach US$ 1437.8 million by 2030, witnessing a CAGR of 4.9% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical......

Global Sleeping Pills Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 94

The global Sleeping Pills market was valued at US$ 2042.3 million in 2023 and is anticipated to reach US$ 2979.5 million by 2030, witnessing a CAGR of 3.8% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estim......

Global Zinc Oral Drops Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85

The global Zinc Oral Drops market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Zinc Oral Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Zinc Oral Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a......

Global Zinc Drops Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85

The global Zinc Drops market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Zinc Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Zinc Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % duri......

Global Anti-Infectives Market Research Report 2024

Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 78

The global Anti-Infectives market was valued at US$ 22700 million in 2023 and is anticipated to reach US$ 27480 million by 2030, witnessing a CAGR of 2.3% during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estima......

We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s. Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors. Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business. Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision. Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us. Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done. Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )

• Ad Hoc
• Pay - as - you - go / Bucket Subscriptions
• Fixed Cost for #of reports
• Customize / Personalize as per your needs